Paper40927638
Targeting Tumor-Associated Hypoxia with Bioreductively Activatable Prodrug Conjugates Derived from Dihydronaphthalene, Benzosuberene, and Indole-based Inhibitors of Tubulin Polymerization.
Shi Z and 15 others. RSC Med Chem, 2025. Cited by 1 paper, by iCite.
Cite this record
ConductScience Library. Targeting Tumor-Associated Hypoxia with Bioreductively Activatable Prodrug Conjugates Derived from Dihydronaphthalene, Benzosuberene, and Indole-based Inhibitors of Tubulin Polymerization. Papers, record 40927638. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/40927638
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
- Title
- Targeting Tumor-Associated Hypoxia with Bioreductively Activatable Prodrug Conjugates Derived from Dihydronaphthalene, Benzosuberene, and Indole-based Inhibitors of Tubulin Polymerization.
- PubMed
Topics0
NLM's MeSH indexing of the paper, its major topics first.
None in this release.
Grants7
Each grant PubMed's record writes, matched to the NIH project NIH's grant and paper links name for this paper, and each of those links the record does not write.
| Grant, as the record writes it | Agency | Country | NIH project | Stated by | Source |
|---|---|---|---|---|---|
| R01 CA140674 | NCI NIH HHS | United States | R01CA140674 | PubMed and NIH | NIH RePORTER |
| S10 RR024757 | NCRR NIH HHS | United States | S10RR024757 | PubMed and NIH | NIH RePORTER |
| R01 CA244579 | NCI NIH HHS | United States | R01CA244579 | PubMed and NIH | NIH RePORTER |
| P30 CA142543 | NCI NIH HHS | United States | P30CA142543 | PubMed and NIH | NIH RePORTER |
| R01 CA238624 | NCI NIH HHS | United States | R01CA238624 | PubMed and NIH | NIH RePORTER |
| HHSN261200800001C | CCR NIH HHS | United States | PubMed | PubMed | |
| HHSN261200800001E | NCI NIH HHS | United States | PubMed | PubMed |
References81
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 26852340 | Design, synthesis, and biological evaluation of water-soluble amino acid prodrug conjugates derived from combretastatin, dihydronaphthalene, and benzosuberene-based parent vascular disrupting agents. | Bioorg Med Chem | 2016 | https://conductscience.org/library/papers/26852340 | PubMed |
| 2 | 23063837 | New strategies for targeting the hypoxic tumour microenvironment in breast cancer. | Cancer Treat Rev | 2013 | https://conductscience.org/library/papers/23063837 | PubMed |
| 3 | 11181500 | P450 enzyme expression patterns in the NCI human tumor cell line panel. | Drug Metab Dispos | 2001 | https://conductscience.org/library/papers/11181500 | PubMed |
| 4 | 6115675 | Stabilization of the colchicine-binding activity of tubulin by organic acids. | Biochim Biophys Acta | 1981 | https://conductscience.org/library/papers/6115675 | PubMed |
| 5 | 16784022 | Current development status of small-molecule vascular disrupting agents. | Curr Opin Investig Drugs | 2006 | https://conductscience.org/library/papers/16784022 | PubMed |
| 6 | 33921719 | Podophyllotoxin: History, Recent Advances and Future Prospects. | Biomolecules | 2021 | https://conductscience.org/library/papers/33921719 | PubMed |
| 7 | 30429970 | Synthesis of dihydronaphthalene analogues inspired by combretastatin A-4 and their biological evaluation as anticancer agents. | Medchemcomm | 2018 | https://conductscience.org/library/papers/30429970 | PubMed |
| 8 | 22184053 | Selective tumor hypoxia targeting by hypoxia-activated prodrug TH-302 inhibits tumor growth in preclinical models of cancer. | Clin Cancer Res | 2012 | https://conductscience.org/library/papers/22184053 | PubMed |
| 9 | 26297733 | Identification of P450 Oxidoreductase as a Major Determinant of Sensitivity to Hypoxia-Activated Prodrugs. | Cancer Res | 2015 | https://conductscience.org/library/papers/26297733 | PubMed |
| 10 | 24183586 | Synthesis of structurally diverse benzosuberene analogues and their biological evaluation as anti-cancer agents. | Bioorg Med Chem | 2013 | https://conductscience.org/library/papers/24183586 | PubMed |
| 11 | 7752190 | Antineoplastic agents. 291. Isolation and synthesis of combretastatins A-4, A-5, and A-6(1a) | J Med Chem | 1995 | https://conductscience.org/library/papers/7752190 | PubMed |
| 12 | 9572894 | Antineoplastic agents. 379. Synthesis of phenstatin phosphate. | J Med Chem | 1998 | https://conductscience.org/library/papers/9572894 | PubMed |
| 13 | 20051957 | Circulating tumour cells demonstrate an altered response to hypoxia and an aggressive phenotype. | Br J Cancer | 2010 | https://conductscience.org/library/papers/20051957 | PubMed |
| 14 | 20501808 | Distinct roles of cytochrome P450 reductase in mitomycin C redox cycling and cytotoxicity. | Mol Cancer Ther | 2010 | https://conductscience.org/library/papers/20501808 | PubMed |
| 15 | 10682679 | NADPH:cytochrome c (P450) reductase activates tirapazamine (SR4233) to restore hypoxic and oxic cytotoxicity in an aerobic resistant derivative of the A549 lung cancer cell line. | Br J Cancer | 2000 | https://conductscience.org/library/papers/10682679 | PubMed |
| 16 | 31002225 | Kinetics-Based Measurement of Hypoxia in Living Cells and Animals Using an Acetoxymethyl Ester Chemiluminescent Probe. | ACS Sens | 2019 | https://conductscience.org/library/papers/31002225 | PubMed |
| 17 | 32196334 | Bioreductively Activatable Prodrug Conjugates of Combretastatin A-1 and Combretastatin A-4 as Anticancer Agents Targeted toward Tumor-Associated Hypoxia. | J Nat Prod | 2020 | https://conductscience.org/library/papers/32196334 | PubMed |
| 18 | 21376230 | Hallmarks of cancer: the next generation. | Cell | 2011 | https://conductscience.org/library/papers/21376230 | PubMed |
| 19 | 23845143 | Bioreductive prodrugs as cancer therapeutics: targeting tumor hypoxia. | Chin J Cancer | 2014 | https://conductscience.org/library/papers/23845143 | PubMed |
| 20 | 9537252 | Reduction of established spontaneous mammary carcinoma metastases following immunotherapy with major histocompatibility complex class II and B7.1 cell-based tumor vaccines. | Cancer Res | 1998 | https://conductscience.org/library/papers/9537252 | PubMed |
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Trials
- Comments and corrections
- Cited by
- Genes
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/40927638
GET https://conductscience.org/api/papers/v1/40927638/references?page=2